Abstract 4209
Background
Vimentin (Vim) is one of the mesenchymal markers, that are often upregulated in cancer cells during epithelial-mesenchymal transition (EMT) – a process endowing tumor cells with invasiveness, pro-metastatic potential and, arguably, cancer stem cells (CSC) properties. It is normally seen in cytoplasm, but cell surface Vim was also detected on cells with CSC characteristics. Vim expression may be used as a surrogate marker of EMT in tumor tissue samples from patients and aid in prognosis evaluation. We aimed to characterize Vim expression in prostate cancer (PCa) using our method of semiquantitative staining assessment.
Methods
Vim expression was assessed in 48 cases of PCa using immunohistochemistry with primary rabbit polyclonal antibodies (ThermoFischer, 1:1000). UnoView Rabbit Detection Kit was used for visualization. Specificity of staining was confirmed by another antibody (mouse monoclonal, DAKO, 1:200) in selected cases. To assess Vim expression semiquantitatively we proposed a weighed staining index (WSI) that takes into account the proportion of stained cells as well as the ratios of staining intensities and can be applied to different cellular compartments staining separately. It combines advantages of simple ad oculus semiquantitative staining evaluation and obtaining numerical characteristics of marker expression.
Results
Median WSI for membranous staining was 5 (0 – 52) (7, if cases without expression were excluded), for cytoplasmic – 20.5 (0 – 64) (22.5, if cases without expression were excluded). In 2 (4.2%) cases marker expression was absent in both membrane and cytoplasm. WSI in PCa was significantly higher for cytoplasmic staining. However, in 3 (6.25%) cases WSI for membranous staining was higher than that for cytoplasmic. Significant correlation was found between WSI for cytoplasmic and membranous staining (Spearman test, r = 0.51, p < 0,05). However, no correlation was found between WSI for both compartments and E-cadherin expression (as assessed by average staining intensity score – a method similar to WSI – using Aperio software previously).
Conclusions
Vim expression as a sign of EMT in the tumor is present in 95.8% cases of PCa and is more prevalent in cytoplasm. WSI is a useful tool to assess Vim (and possibly other markers) expression.
Clinical trial identification
Legal entity responsible for the study
M. Puchinskaya.
Funding
Belarusian Republican Foundation for Fundamental Research.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3683 - Impact of Radiotherapy on efficacy of anti-programmed death 1 (PD-1) antibodies in metastatic NSCLC
Presenter: Evangeline Samuel
Session: Poster Display session 1
Resources:
Abstract
3924 - Pembrolizumab frontline monotherapy in patients with NSCLC and high PD-L1 expression: Real World Data from a European Cohort with focus on subgroups of interest
Presenter: Giannis Mountzios
Session: Poster Display session 1
Resources:
Abstract
3970 - Patients with metastatic non-small cell lung cancer and PD-L1 expression in Germany. Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315)
Presenter: Martin Sebastian
Session: Poster Display session 1
Resources:
Abstract
5350 - The efficacy and safety of pembrolizumab as a first-line therapy in PD-L1 50% positive advanced NSCLC (HOPE-001)
Presenter: Motohiro Tamiya
Session: Poster Display session 1
Resources:
Abstract
3832 - Osimertinib in epidermal growth factor receptor (EGFR) T790M advanced non-small cell lung cancer (NSCLC): analysis of patients with central nervous system (CNS) metastases in a real-world study (ASTRIS)
Presenter: Giulio Metro
Session: Poster Display session 1
Resources:
Abstract
4082 - Real-world (RW) treatment patterns and outcomes for second-line (2L) therapy and beyond in patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC receiving a first-line (1L) first- or second-generation (1G/2G) EGFR tyrosine kinase inhibitor (TKI)
Presenter: Riyaz Shah
Session: Poster Display session 1
Resources:
Abstract
2855 - Impact of ramucirumab (RAM) + erlotinib (ERL) on EGFR mutations in circulating tumor DNA – The 1st report of a biomarker study in Japanese patients from RELAY: Global Ph3 study of ERL + RAM or placebo (PL) in 1L metastatic NSCLC with EGFR activating mutations
Presenter: Kazuto Nishio
Session: Poster Display session 1
Resources:
Abstract
2911 - Apatinib combined with EGFR - TKI in treating advanced non-small cell lung cancer with EGFR - TKI resistance
Presenter: Ruifen Tian
Session: Poster Display session 1
Resources:
Abstract
2100 - Updated analysis of a phase I trial of afatinib (Afa) and bevacizumab (Bev) in chemo-naïve patients (pts) with advanced non-small-cell lung cancer (NSCLC) harboring EGFR-mutations: OLCSG1404
Presenter: Takashi Ninomiya
Session: Poster Display session 1
Resources:
Abstract
4325 - Multiple synchronous mechanisms may contribute to osimertinib resistance in non-small cell lung cancer (NSCLC) patients: insights of the MATCH-R study
Presenter: Diego Enrico
Session: Poster Display session 1
Resources:
Abstract